Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 8/20 | 0.38 |
| ▸ | UGCG | Q16739 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | USP1 | O94782 | 2/20 | 0.36 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4782916 | 0.87 | CCR9 (0.43) | EGLN3MEN1KMT2ACCR9USP1 | |
| SCHEMBL4737534 | 0.82 | EGLN3 (0.44) | EGLN3MEN1KMT2ACCR9RIPK3 | |
| SCHEMBL4739209 | 0.82 | EGLN3 (0.46) | EGLN3MEN1KMT2ACCR9POLB | |
| SCHEMBL4739981 | 0.81 | EGLN3 (0.56) | EGLN3MEN1KMT2ACCR9POLB | |
| SCHEMBL4736971 | 0.81 | EGLN3 (0.45) | EGLN3MEN1KMT2ACCR9PPARG | |
| SCHEMBL4741832 | 0.80 | CCR9 (0.44) | EGLN3MEN1KMT2ACCR9POLB | |
| SCHEMBL4741831 | 0.78 | EGLN3 (0.48) | EGLN3MEN1KMT2ACCR9 | |
| SCHEMBL4740088 | 0.77 | CCR9 (0.45) | EGLN3MEN1KMT2ACCR9TP53 | |
| SCHEMBL5000326 | 0.77 | CCR9 (0.47) | EGLN3MEN1KMT2ACCR9TP53 | |
| SCHEMBL4741292 | 0.77 | EGLN3 (0.73) | EGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN3 3/4885MEN1 2935/4885KMT2A 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.